Pherecydes Pharma Has Submitted An Application For The Approval Of A Phase I Clinical Study In Infective Endocarditis Caused By Staphylococcus Aureus streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
The study should include 12 patients, and its launch is expected in the third quarter of 2023NANTES, France (BUSINESS WIRE) Regulatory News:Pherecydes Pharma (FR0011651694 - ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today ann.